C07K14/165

A VACCINE AGAINST SARS-COV-2 AND PREPARATION THEREOF
20230174588 · 2023-06-08 ·

The current invention provides a DNA construct comprising S gene or S1 gene region of 2019-nCoV spike-S protein. The DNA construct of the present invention comprises DNA plasmid vector carrying S gene or S1 gene region of 2019-nCoV spike-S protein. The vector may further comprise a gene encoding IgE signal peptide or a gene encoding t-PA signal peptide. The DNA construct according to the present invention is further used in the preparation of an immunogenic composition or a vaccine for treating or preventing corona virus or its related diseases.

DETECTION REAGENT FOR SCREENING BLOCKING AGENT OF CORONAVIRUS INFECTIONS, AND DETECTION METHOD

Disclosed are a fusion protein probe and a cell model for screening a blocking agent of coronavirus infections, a screening system comprising same, and a method of using the screening system for screening a blocking agent of coronavirus infections. The screening system and method do not involve live viruses, are simple and convenient to operate, have a high accuracy, are suitable for high throughput screening, and are of great significance for the development of coronavirus neutralizing antibodies, preventive vaccines, and small molecule drugs.

DETECTION REAGENT FOR SCREENING BLOCKING AGENT OF CORONAVIRUS INFECTIONS, AND DETECTION METHOD

Disclosed are a fusion protein probe and a cell model for screening a blocking agent of coronavirus infections, a screening system comprising same, and a method of using the screening system for screening a blocking agent of coronavirus infections. The screening system and method do not involve live viruses, are simple and convenient to operate, have a high accuracy, are suitable for high throughput screening, and are of great significance for the development of coronavirus neutralizing antibodies, preventive vaccines, and small molecule drugs.

LARGE SEQUENCE PAN-CORONAVIRUS VACCINE COMPOSITIONS
20230173060 · 2023-06-08 ·

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CD8 T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

SARS-CORONAVIRUS 2 (SARS-COV-2) SUBUNIT VACCINE CANDIDATES
20230167159 · 2023-06-01 ·

A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

SARS-CORONAVIRUS 2 (SARS-COV-2) SUBUNIT VACCINE CANDIDATES
20230167159 · 2023-06-01 ·

A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

NUCLEIC ACID BASED VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS
20220054629 · 2022-02-24 · ·

An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.

Vaccine for Use in Protecting a Pig Against Porcine Endemic Diarrhea Virus

The invention pertains to a vaccine for use in protecting a pig against an infection with porcine endemic diarrhea virus (PEDV), the vaccine comprising non-live PEDV antigen and a non-metabolizable oil containing adjuvant, wherein the total amount of oil in the vaccine is less than 50% v/v, by administration of a dose of the antigen corresponding to at least 3.0E6 TCID50 killed whole PEDV. The invention also pertains to a method of protecting a pig against an infection with porcine endemic diarrhea virus.

Vaccine for Use in Protecting a Pig Against Porcine Endemic Diarrhea Virus

The invention pertains to a vaccine for use in protecting a pig against an infection with porcine endemic diarrhea virus (PEDV), the vaccine comprising non-live PEDV antigen and a non-metabolizable oil containing adjuvant, wherein the total amount of oil in the vaccine is less than 50% v/v, by administration of a dose of the antigen corresponding to at least 3.0E6 TCID50 killed whole PEDV. The invention also pertains to a method of protecting a pig against an infection with porcine endemic diarrhea virus.

VACCINE GENERATION
20220054149 · 2022-02-24 ·

An apparatus for vaccine generation includes a syringe with a cavity that includes a solution with photosensitizers. Microbial particles are added to the solution. A light source is capable of emitting one or more wavebands of light that are effectively absorbed by the one photosensitizers to generate singlet oxygen in the solution and other radical species that rapidly react with and damage lipids, proteins, DNA, and RNA of the microbial particles. This damage produces immunogens that can be applied as a vaccine to viruses and other infectious microbial particles. A plunger that fits within a proximal opening in the syringe is used for forcing the solution including the immunogens through the filter and out of the syringe while the photosensitizers, debris and unwanted microbial particles are trapped within the filter.